期刊名称：EMERGING INFECTIOUS DISEASES
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
- Recognition of new and reemerging infections and understanding of factors involved in disease emergence, prevention, and elimination. Toward this end, the journal:
- Investigates factors known to influence emergence: microbial adaptation and change, human demographics and behavior, technology and industry, economic development and land use, international travel and commerce, and the breakdown of public health measures.
- Reports laboratory and epidemiologic findings within a broader public health perspective.
- Provides swift updates of infectious disease trends and research: new methods of detecting, characterizing, or subtyping pathogens; developments in antimicrobial drugs, vaccines, and prevention or elimination programs; case reports.
- Fast and broad dissemination of reliable information on emerging infectious diseases. Toward this end, the journal:
- Publishes reports of interest to researchers in infectious diseases and related sciences, as well as to public health generalists learning the scientific basis for prevention programs.
- Encourages insightful analysis and commentary, stimulating global interest in and discussion of emerging infectious disease issues.
- Harnesses electronic technology to expedite and enhance global dissemination of emerging infectious disease information.
|
|
Instructions to Authors
For information about editorial policy visit http://www.cdc.gov/ncidod/eid/about/ed_policy.htm.
Manuscript Preparation
Submit Manuscript
For word processing, use MS Word. Create tables within MS Word's table tool. Do not format tables as columns or tabs. Do not use endnotes for references. Send graphics in native, high-resolution (200 dpi minimum) .TIF (Tagged Image File), or .EPS (Encapsulated Postscript) format. Graphics should be in a separate electronic file from the text file. For graphic files, use Arial font. Convert Macintosh files into the suggested PC format.
Begin each of the following sections on a new page and in this order: title page, keywords, abstract, text, acknowledgments, first author's biographical sketch, references, tables, figure legends, appendixes, and figures. Each figure should be in a separate file.
Title Page
Give complete information about each author (i.e., full name, graduate degree(s), affiliation, and the name of the institution in which the work was done). Clearly identify the corresponding author and provide that author's address (include phone number, fax number, and e-mail address). Include separate word counts for both the abstract and the body of the text.
Keywords and Abstract
Include up to 10 keywords; use terms listed in the Medical Subject Headings from Index Medicus. Do not cite references in the abstract. Abstracts for perspectives, synopses, policy reviews, and research studies should not exceed 150 words. Abstracts for dispatches should be no more than 50 words.
Text
Double-space everything, including the title page, abstract, references, tables, and figure legends. After a period, leave only one space before beginning the next sentence. Use 12-point Times New Roman font and format with ragged right margins (left align). Italicize (rather than underline) scientific names when needed.
Biographical Sketch
Include a short biographical sketch of the first author (both authors if only two). Include affiliations and the author's primary research interests.
References
Follow Uniform Requirements style (see Style Guide for URL). Place reference numbers in parentheses, not superscripts. Number citations in order of appearance (including in text, figures, and tables). Cite personal communications, unpublished data, and manuscripts in preparation or submitted for publication in parentheses in text. Consult List of Journals Indexed in Index Medicus for accepted journal abbreviations; if a journal is not listed, spell out the journal title in full. List the first six authors followed by "et al." Below are some examples of references that may not be listed in Uniform Requirements.
Electronic Journal Citation
Komar N, Lanciotti R, Bowen R, Langevin S, Bunning M. Detection of West Nile virus in oral and cloacal swabs collected from bird carcasses. Emerg Infect Dis [serial online] 2002 Jul [cited 2002 May 30];8. Available from: URL: http://www.cdc.gov/ncidod/EID/vol8no7/02-0157.htm
ProMed Citation
Lipkin I. West Nile-like virus: PCR primers and protocols. ProMed. October 13, 1999. Accessed at: http://www.promedmail.org, archive number: 19991013.1826.
Published Conference Abstract Citation
Galil K, Singleton R, Levine O, Fitzgerald M, Ajello G, Bulkow L, et al. High prevelence of Haemophilus influenzae type b (Hib) carriage among Alaska Natives despite widespread use of Hib-conjugate vaccine. In: Abstracts of the 35th Infectious Diseases Society of America; San Francisco, California; 1997 Sept 13-16; Abstract 421. Alexandria, (VA): Infectious Disease Society of America; 1997.
Tables and Figures
Tables must be created with MS Word's table tool. Using columns and tabs within the word processing program is never acceptable, and the tables will be returned to the author for proper formatting. For figures, use color only as needed; send files, slides, photographs, or prints. Figures should be sent in separate files and not be included with the manuscript. Use Arial for figure lettering. Figures, symbols, lettering, and numbering should be clear and large enough to remain legible when reduced. Place figure keys within the figure. For more information access and search the EID Style Guide.
Back to top
Manuscript Submission
To submit a manuscript access Manuscript Central from the Emerging Infectious Diseases Web page. Include a cover letter indicating the proposed category of the article (e.g., research, dispatch) and include the submission checklist. After you have received acknowledgment of manuscript receipt, use assigned manuscript number in all correspondence.
Back to top
Types of Articles
Perspectives
Articles should be under 3,500 words and should include references, not to exceed 40. Use of subheadings in the main body of the text is recommended. Photographs and illustrations are encouraged. Provide a short abstract (150 words) and a brief biographical sketch of first author. Articles in this section should provide insightful analysis and commentary about new and reemerging infectious diseases and related issues. Perspectives may also address factors known to influence the emergence of diseases, including microbial adaptation and change, human demographics and behavior, technology and industry, economic development and land use, international travel and commerce, and the breakdown of public health measures. If detailed methods are included, a separate section on experimental procedures should immediately follow the body of the text.
Synopses
Articles should be under 3,500 words and should include references, not to exceed 40. Use of subheadings in the main body of the text is recommended. Photographs and illustrations are encouraged. Provide a short abstract (150 words) and a brief biographical sketch of first author¡ªboth authors if only two. This section comprises concise reviews of infectious diseases or closely related topics. Preference is given to reviews of new and emerging diseases; however, timely updates of other diseases or topics are also welcome. If detailed methods are included, a separate section on experimental procedures should immediately follow the body of the text.
Research Studies
Articles should be under 3,500 words and should include references, not to exceed 40. Use of subheadings in the main body of the text is recommended. Photographs and illustrations are encouraged. Provide a short abstract (150 words) and a brief biographical sketch of first author¡ªboth authors if only two. These articles report laboratory and epidemiologic results within a public health perspective. Although these reports may be written in the style of traditional research articles, they should explain the value of the research in public health terms and place the findings in a larger perspective (i.e., "Here is what we found, and here is what the findings mean").
Policy and Historical Reviews
Articles should be under 3,500 words and should include references, not to exceed 40. Use of subheadings in the main body of the text is recommended. Photographs and illustrations are encouraged. Provide a short abstract (150 words) and a brief biographical sketch. Articles in this section include public health policy or historical reports that are based on research and analysis of emerging disease issues.
Dispatches
Articles should be 1,000 to 1,500 words and need not be divided into sections. If subheadings are used, they should be general, e.g., "The Study" and "Conclusions." Provide a brief abstract (50 words); references (not to exceed 15); figures or illustrations (not to exceed two); tables (not to exceed two); and a brief biographical sketch of first author¡ªboth authors if only two. Dispatches are updates on infectious disease trends and research. The articles include descriptions of new methods for detecting, characterizing, or subtyping new or reemerging pathogens. Developments in antimicrobial drugs, vaccines, or infectious disease prevention or elimination programs are appropriate. Case reports are also welcome.
Commentaries
Thoughtful discussions (500 to 1,000 words) of current topics. Commentaries should not include figures or tables.
Another Dimension
Thoughtful essays, short stories, or poems on philosophical issues related to science, medical practice, and human health. Topics may include science and the human condition, the unanticipated side of epidemic investigations, or how people perceive and cope with infection and illness. This section is intended to invoke compassion for human suffering and to expand the science reader's literary scope. Manuscripts are selected for publication as much for their content (the experiences they describe) as for their literary merit.
Letters
This section includes letters that present preliminary data or comment on published articles. Letters (500 to 1,000 words) should not be divided into sections, nor should they contain figures or tables. References (not more than 10) may be included.
Book Reviews
Short reviews (250 to 500 words) of recently published books on emerging disease issues are welcome. The name of the book and publisher, and the number of pages should be included, as well as price and ISBN #.
Announcements
We welcome brief announcements (50 to 150 words) of timely events of interest to our readers. (Announcements may be posted on the journal Web page only, depending on the event date.)
Conference Summaries
Summaries (500 to 1,000 words) of emerging infectious disease conference proceedings. Summaries may provide references to a full report of conference activities and should focus on the meeting's content.
Editorial Board
Editors
D. Peter Drotman, Editor-in-Chief | David Bell, Associate Editor | Patrice Courvalin, Associate Editor | Brian W.J. Mahy, Associate Editor | Martin I. Meltzer, Associate Editor | David Morens, Associate Editor | Tanja Popovic, Associate Editor | Gabriel Rabinovich, Associate Editor | Mario Raviglione, Associate Editor | Patricia M. Quinlisk, Associate Editor | Polyxeni Potter, Managing Editor | Joseph E. McDade, Founding Editor
 D. Peter Drotman, MD, MPH
Editor-in-Chief
Atlanta, Georgia, USA
dpd1@cdc.gov
Peter Drotman started his career at the Centers for Disease Control and Prevention as an Epidemic Intelligence Service officer. Before his current assignment as senior medical officer, National Center for Infectious Diseases, he served as assistant director for Public Health and Science, Division of HIV/AIDS Prevention, and assistant to the director, Division of HIV/AIDS. He has a broad background in clinical practice, public health, infectious diseases, and epidemiologic science and holds appointments as clinical assistant professor in the Departments of Medicine and Family and Preventive Medicine, Emory University School of Medicine, Atlanta, Georgia. Dr. Drotman, who has published extensively on AIDS and other infectious diseases, has served on the HIV/AIDS Worldwide Web Site Editorial Panel of the American Medical Association, as infectious diseases Chapter Editor of the National Organization for Rare Diseases, and as acting editor-in-chief for selected issues of the Morbidity and Mortality Weekly Report.
 David M. Bell, MD
Associate Editor
Atlanta, Georgia, USA
dmb1@cdc.gov
David M. Bell is Assistant Director for Antimicrobial Resistance, National Center for Infectious Diseases, Centers for Disease Control and Prevention. In this capacity, he coordinates agency efforts to address emerging resistance to antimicrobial agents. Dr. Bell, also clinical assistant professor of pediatric infectious diseases at Emory University School of Medicine, Atlanta, Georgia, co-chairs the U.S. Federal Interagency Task Force on Antimicrobial Resistance and is a member of the U.S. Food and Drug Administration's Anti-Infective Drug Advisory Committee (for human drugs) and the American Veterinary Medical Association's Committee on Antimicrobial Resistance.
 Patrice Courvalin, MD. MS
Associate Editor
Paris, France
pcourval@pasteur.fr
Patrice Courvalin, professor and head of the Antibacterial Agents Unit, National Reference Center for Antibiotics, and Department of Fundamental and Medical Microbiology, Institut Pasteur, Paris, has held many positions at the Institut since he started working there in 1969. A member of multiple committees and professional organizations in Europe and around the world and a prolific author on infectious diseases and antimicrobial resistance topics, Dr. Courvalin serves on the editorial board of several international journals.
 Brian W.J. Mahy, BSc, MA, PhD, ScD, DSc
Associate Editor
Atlanta, Georgia, USA
bxm1@cdc.gov
Brian Mahy, senior scientific advisor, National Center for Infectious Diseases, and adjunct professor, Department of Microbiology, Emory University, came to the Centers for Disease Control and Prevention (CDC) in 1989 as director, Division of Viral Diseases. Before coming to CDC, Dr. Mahy was head of the Division of Virology, Department of Pathology, Cambridge University, UK, and director, Animal Virus Research Institute, Pirbright, Surrey, UK, which houses the World Reference Laboratory for Foot and Mouth Disease. He served as President of the International Union of Microbiological Societies (1999¨C2002) and is a Fellow of the American Academy of Microbiology. A world-renowned virologist and prolific author, Dr. Mahy has served as editor-in-chief of several virology journals.
 Martin I. Meltzer, Ph.D
Associate Editor
Atlanta, Georgia, USA
qzm4@cdc.gov
Martin Meltzer is Senior Health Economist, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). His research interests include cost-benefit and cost-effectiveness analyses of health interventions and policy guidelines for use of health technologies, such as vaccines. Much of his work is multidisciplinary and has included modeling of potential responses to smallpox as a bioterrorist weapon; evaluating the cost effectiveness of Lyme disease and hepatitis A vaccination; assessing the economic impact of infectious diseases, from pandemic influenza to dengue; and modeling of raccoon rabies control by oral vaccine. Dr. Meltzer has published more than 100 publications and has received many honors and awards, among them, CDC's Charles C. Shepard award and the James H. Nakano citation. He serves as guest editor and was a member of the editorial board of Agriculture and Human Values, helps coordinate reviews of manuscripts on health economics for The Lancet, and has refereed manuscripts for 15 other journals.
 David Morens, MD
Associate Editor
Bethesda, Maryland, USA
dm270q@nih.gov
David Morens, medical historian and professor, University of Hawaii School of Medicine since 1982, took academic leave of absence in 1999 to work at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. Dr. Morens' research interests include viral disease pathogenesis, epidemiology, and the relationship between biomedical research and public health.
 Tanja Popovic, MD, PhD
Associate Editor
Atlanta, Georgia, USA
TPopovic@cdc.gov
Tanja Popovic started her career at the Centers for Disease Control and Prevention as a Fulbright Postdoctoral Fellow. Now chief of Epidemiologic Investigations Laboratory, Meningitis and Special Pathogens Branch, Dr. Popovic is an expert in laboratory aspects of anthrax, brucellosis, melioidosis, and glanders. In addition to bioterrorism preparedness and response, her research interests include laboratory diagnosis and molecular epidemiology of bacterial vaccine-preventable diseases. Dr. Popovic, who has published more than 100 articles in her diverse areas of research, is co-director of the World Health Organization's Collaborating Center for the Prevention and Control of Epidemic Meningitis. She is also a Fellow of the American Academy of Microbiology, a member of the American Society for Microbiology International Committee, and a Waksman Foundation Lecturer.
 Gabriel Rabinovich, PhD
Associate Editor
Buenos Aires, Argentina
gabyrabi@ciudad.com.ar
Gabriel Rabinovich is research associate investigator, Division of Immunogenetics, Hospital de Cl¨¬nicas Jos¨¦ de San Mart¨ªn, School of Medicine, University of Buenos Aires, and associate investigator, National Research Council, CONICET, Argentina. Dr. Rabinovich is a prolific author in molecular immunology and glycoimmunology and has been widely recognized for his work in molecular immunopathology.
 Mario C. Raviglione, MD
Associate Editor
Geneva, Switzerland
raviglionem@who.int
Mario Raviglione is acting director of the StopTB Department, World Health Organization (WHO), in Geneva, Switzerland. Dr. Raviglione joined WHO to work on tuberculosis (TB) in 1991 after training in internal medicine and infectious diseases in New York and Boston, where he was AIDS Fellow at Beth Israel Hospital, Harvard Medical School. At WHO, in the mid-1990s, he became responsible for setting up the global TB surveillance and monitoring system and, in the late-1990s, for directing TB strategy and operations. His activities have encompassed a range of fields: morbidity surveillance and program monitoring, drug-resistance surveillance, operational research on community and private practioner involvement in TB control, TB/HIV interaction, MDR-TB management in developing countries, and control efforts and DOTS expansion worldwide. Dr. Raviglione is author of more than 110 articles, book chapters, and other publications.
 M. Patricia Quinlisk, MD, MPH
Associate Editor
Des Moines, Iowa, USA
pquinlis@idph.state.ia.us
Patricia Quinlisk is medical director and state epidemiologist of the Iowa Department of Public Health. A former president of the Council of State and Territorial Epidemiologists, Dr. Quinlisk serves, or has served, on several national advisory committees, including the Department of Defense's Panel to Assess the Capabilities for Domestic Response to Terrorist Acts Involving Weapons of Mass Destruction (the Gilmore Commission), several Institute of Medicine Committees, and the National Center for Infectious Diseases' Board of Scientific Counselors.
 Polyxeni Potter, MA, ELS
Managing Editor
Atlanta, Georgia, USA
pmp1@cdc.gov
Polyxeni Potter, a former Fulbright scholar from Cyprus, came to the Centers for Disease Control and Prevention (CDC) from Georgia State University, Atlanta, Georgia, where she taught English language classes. At CDC, she worked as writer and editor and then as chief of publication activities at the National Center for Infectious Diseases until 1995. Managing Editor of Emerging Infectious Diseases since its inception, Ms. Potter, who has a strong interest in literature and the arts, guides the Another Dimension manuscript category and the journal's cover activities.
 Joseph E. McDade, PhD
Founding Editor
Atlanta, Georgia, USA
jem3@cdc.gov
Joseph McDade, founding editor of Emerging Infectious Diseases, continues to serve the journal in an advisory capacity. Dr. McDade spent most of his career at the Centers for Disease Control and Prevention (CDC), as research microbiologist and eventually as deputy director, National Center for Infectious Diseases. Author of approximately 100 scientific articles, Dr. McDade is best known for isolating and identifying Legionella pneumophila, the bacterium that causes Legionnaires' disease; for identifying the cause of ehrlichiosis, an emerging tickborne illness; and for directing research on Rocky Mountain spotted fever, Q fever, and typhus. Dr. McDade has also served as adjunct professor at Emory University's School of Public Health, Atlanta, Georgia, and since his retirement from CDC in 2001, as adjunct professor at Shorter and Floyd Colleges in Rome, Georgia.
|
刊名字顺( Alphabetical List of Journals):
返回页首 